Hcw Biologics Revenue Plunges 98 Percent

Hcw Biologics (NASDAQ:HCWB), a biotechnology company specializing in novel immunotherapies targeting age-related and inflammatory diseases, released its second quarter 2025 earnings on August 14, 2025. The most important news is an ongoing collapse in revenue, with only $6,550 (GAAP) recognized, missing analyst expectations of $7.0 million. However, the company sharply narrowed its net loss to $1.9 million (GAAP), primarily due to reduced legal expenses, down from a $15.3 million GAAP net loss in Q2 2024. Performance was mixed—cost controls and legal resolutions improved results, but revenue underperformance and continued balance sheet stress stand out as significant issues. Source: Analyst estimates for the quarter provided by FactSet. HCW Biologics develops immunotherapies aimed at treating diseases driven by chronic inflammation and immune dysfunction. Its core business utilizes two proprietary platforms: TOBI, which creates fusion-protein drugs, and TRBC, which engineers immunotherapies for cancer and autoimmune diseases.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool